Optimising Treatment in Relapsed Refractory Multiple
Sonneveld P De Wit E Moreau P. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients Crit Rev Oncol Hematol. 153–70. Blimark C Turesson I Genell A et al. Outcome and survival of myeloma patients diagnosed .
Get Price
Treatment strategies in relapsed and refractory multiple
Initially introduced in the relapsed setting the novel agents namely thalidomide bortezomib and lenalidomide are now being increasingly incorporated into upfront treatment strategies raising questions about the feasibility of retreatment with such agents.
Get Price
Treatment of relapsed and refractory multiple myeloma
Treatment of relapsed and refractory disease in . patients who have received one previous line of therapy. The most important question for most cases of myeloma relapse or disease that is resistant to therapy is whether . a patient has lenalidomide-refractory disease or not (figure 1). A second consideration that will be increasingly
Get Price
Improving Patient-Centered Care in Relapsed/Refractory DLBCL
May 14 2020 · Evaluate strategies for overcoming real-world barriers to team-based patient-centered care in the relapsed/refractory DLBCL setting Assess the efficacy and safety of novel treatment options for relapsed/refractory DLBCL Apply emerging evidence guidelines and expert consensus to personalized treatment decision-making in relapsed/refractory
Get Price
Treatment of relapsed and refractory multiple myeloma
The therapeutic strategy for relapsed and refractory multiple myeloma (RRMM) integrates a holistic approach regarding patient disease and drug-related factors. Patient-related factors include age frailty status and underlying comorbidities especially cardiovascular and renal diseases and peripheral neuropathies that affect tolerability to
Get PriceHow I treat relapsed and refractory Hodgkin lymphoma
Relapsed or refractory Hodgkin lymphoma is a challenging problem for clinicians who treat hematologic malignancies. The standard management of these patients should include the use of salvage chemotherapy followed by autologous stem cell transplant (ASCT) in
Get Price
Understanding New Treatment Options for Patients with
There has been tremendous growth over the years in terms of treatment options for patients with multiple myeloma. That growth has extended to patients in the relapsed and refractory setting who often face an even more complex disease than patients with traditional multiple myeloma.
Get PriceTreatment strategies in relapsed and refractory multiple
Oct 25 2011 · If relapse occurs within a short time (<6–12 months) or while the patient is still undergoing treatment this likely indicates an aggressive disease (relapsed-and-refractory
Get Price
Improving Patient-Centered Care in Relapsed/Refractory DLBCL
May 14 2020 · Evaluate strategies for overcoming real-world barriers to team-based patient-centered care in the relapsed/refractory DLBCL setting Assess the efficacy and safety of novel treatment options for relapsed/refractory DLBCL Apply emerging evidence guidelines and expert consensus to personalized treatment decision-making in relapsed/refractory
Get Price
How I manage patients with relapsed/refractory diffuse
May 29 2018 · Despite progress in the upfront treatment of diffuse large B cell lymphoma (DLBCL) patients still experience relapses. Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second‐line treatment for relapsed and refractory (R/R) DLBCL.
Get Price
Treatment strategies in relapsed and refractory multiple
Initially introduced in the relapsed setting the novel agents namely thalidomide bortezomib and lenalidomide are now being increasingly incorporated into upfront treatment strategies raising
Get Price
Navigating the Complexities of Relapsed/Refractory
Dec 30 2020 · Thus the goal of therapy for patients with relapsed/refractory multiple myeloma (RRMM) is to promote deep and durable remissions. In this case-based activity an expert in multiple myeloma provides a comprehensive review of evidence-based management strategies including combination therapy recommended sequencing and maintenance treatment.
Get Price
Treatment Strategies for Relapsed/Refractory HER2 MBC
Treatment Strategies for Relapsed/Refractory HER2 MBC. February 23 2021. EP. 1 Best Practices HER2 MBC With Brain Mets. EP. 2 Frontline Standards of Care for HER2 MBC. There s a lot of good stuff. What factors are important when considering a treatment approach for a patient with HER2 human epidermal growth factor receptor 2
Get Price
Carfilzomib Based Treatment Strategies in the Management
Published experience with carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD. We retrospectively analyzed 45 patients with extramedullary RRMM treated with carfilzomib from June 2013 to September 2019.
Get Price
Treatment strategies for relapsed and refractory
The treatment of refractory or relapsed aggressive non-Hodgkin s lymphoma (NHL) in patients in a state of poor health is difficult due to their ineligibility to receive intensive salvage chemotherapy.
Get Price
Treatment strategies for relapsed and refractory
The treatment of refractory or relapsed aggressive non-Hodgkin s lymphoma (NHL) in patients in a state of poor health is difficult due to their ineligibility to receive intensive salvage chemotherapy.
Get Price
How I treat relapsed and refractory Hodgkin lymphoma
Relapsed or refractory Hodgkin lymphoma is a challenging problem for clinicians who treat hematologic malignancies. The standard management of these patients should include the use of salvage chemotherapy followed by autologous stem cell transplant (ASCT) in
Get Price
Treatment strategies in relapsed and refractory multiple
Initially introduced in the relapsed setting the novel agents namely thalidomide bortezomib and lenalidomide are now being increasingly incorporated into upfront treatment strategies raising questions about the feasibility of retreatment with such agents.
Get PriceNovel Therapies for the Treatment of Relapsed/Refractory
Target Audience and Goal Statement. This activity is intended for hematology/oncology specialists. The goal of this activity is to improve the knowledge of hematologists and oncologists regarding available and novel treatments for relapsed/refractory (R/R) peripheral T-cell lymphomas (PTCL) and their potential role in the treatment paradigm.
Get Price
Integrating New Approaches for Treating Relapsed
Lonial S Dimopoulos M Palumbo A et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. . Lonial S Lee HC Badros A et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2) a two-arm randomised open-label phase 2 study. Lancet Oncol. 2020 21
Get Price
Hodgkin Lymphoma Relapsed/RefractoryLRF
Hodgkin lymphoma patients who fail to achieve complete remission following frontline therapy or who relapse after achieving complete remission are often treated with second-line chemotherapy regimens followed by a bone marrow or stem cell transplant. A transplant of bone marrow or stem cells is needed to restore healthy bone marrow.
Get Price
Hodgkin Lymphoma Relapsed/RefractoryLRF
Hodgkin lymphoma patients who fail to achieve complete remission following frontline therapy or who relapse after achieving complete remission are often treated with second-line chemotherapy regimens followed by a bone marrow or stem cell transplant. A transplant of bone marrow or stem cells is needed to restore healthy bone marrow.
Get Price
(PDF) Contemporary patient-tailored treatment strategies
Refractory or Relapsed and Refractory Multiple Myeloma 3 Please cite this articl e as F.M. Uck un S. Qazi T. Demirer et al. Con temporar y patient -tailored treatment st rategies against hi
Get PriceImproving Patient-Centered Care in Relapsed/Refractory DLBCL
May 14 2020 · Evaluate strategies for overcoming real-world barriers to team-based patient-centered care in the relapsed/refractory DLBCL setting Assess the efficacy and safety of novel treatment options for relapsed/refractory DLBCL Apply emerging evidence guidelines and expert consensus to personalized treatment decision-making in relapsed/refractory
Get Price
Treatment of refractory and relapsed small cell lung
Nov 24 2020 · The treatment of relapsed and refractory SCLC will be reviewed here. The initial management of SCLC and experimental approaches to treatment are considered separately. (See "Extensive-stage small cell lung cancer Initial management" and "Limited-stage small cell lung cancer Initial management".)
Get Price
Carfilzomib Based Treatment Strategies in the Management
Published experience with carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD. We retrospectively analyzed 45 patients with extramedullary RRMM treated with carfilzomib from June 2013 to September 2019.
Get Price
PRIME® PodcastTargeted Therapies in Relapsed/Refractory
Apr 02 2021 · Update on Treatment Options for Relapsed/Refractory MM Case-Based Discussions Personalizing Treatment Decision-Making Patient refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) Patient refractory to IMiDs PIs and anti-CD38 therapy Considerations in the time of COVID-19
Get Price
Challenges in the management and treatment of patients
Challenges in the management and treatment of patients with relapsed/refractory DLBCL. The virtual Lymphoma Hub Satellite Symposium at the European School of Haematology (ESH) s 2nd How to Diagnose and Treat Lymphoma conference saw a panel of international experts come together to discuss how to manage patients with relapsed and/or
Get Price
How I manage patients with relapsed/refractory diffuse
how to manage relapsed or refractory DLBCL (RR-DLBCL) as well as to provide novel strategies in multiple relapsed DLBCL. We consider different issues factors affecting survival type of salvage regimen type of conditioning regimen treatment post-ASCT and strategies for patients
Get Price
Treating Strategies for Patients With Relapsed/Refractory
Jul 01 2020 · Patients with relapsed or refractory AML who received venetoclax alone demonstrated a 19 response rate compared to more than 70 among newly diagnosed older adult patients (ineligible for standard induction therapy) who
Get Price
